Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025. The company released its annual report for 2025 on September 25, in which it reported a 49% growth in global revenue for fiscal year 2025. It stated that much of the growth was due to robust sales of its flagship traveler’s diarrhea product, Travelan. North American sales for Travelan increased by 76% to A$2 million, attributed to Amazon and Canadian retail growth. Australian sales rose 40$5.3 million, aided by new pharm ...